INDIA LIFE SCIENCES FUND IV DOMESTIC
Raised
$2M
Investors
3
Min Invest
$0
AltStreet Analysis
·Generated from EDGAR primary sources
INDIA LIFE SCIENCES FUND IV DOMESTIC is a pooled investment fund operating under Rule 506(b) and 3(c)(1) exemptions. This amended filing reports $1.6M raised from 3 investors. The fund is incorporated in India and managed by executive officers Shweta Agrawal, Jeevak Gupta, and Anil Jagirdar.
This India-domiciled life sciences fund follows a standard 506(b)/3(c)(1) private fund structure typical of institutional alternative investments. The filing does not disclose minimum investment thresholds or first sale date, consistent with platform conventions for institutional fund vehicles that maintain detailed terms in private placement memoranda.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Shweta Agrawal
Executive Officer · Hyderabad, Telangana, K7
Jeevak Gupta
Executive Officer · Hyderabad, Telangana, K7
Anil Jagirdar
Executive Officer · Hyderabad, Telangana, K7
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
